What question did this study set out to answer?

To assess whether adjuvant exemestane combined with ovarian suppression improves outcomes compared to tamoxifen plus ovarian suppression in premenopausal women with hormone-receptor-positive early breast cancer.

June 1, 2014New England Journal of MedicineOpen Access

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

View Full Paper

Ask AI

Bookmark

Authors

OPOlivia PaganiSwiss Group For Clinical Cancer Research MRMeredith M. ReganUniversità Cattolica del Sacro Cuore BWBarbara WalleyUniversity of Calgary

Discussion

Member takes

Implication

Randomized trials demonstrate reduced recurrence with exemestane plus ovarian suppression in premenopausal women, highlighting improved adjuvant endocrine therapy.

Key Points

To assess whether adjuvant exemestane combined with ovarian suppression improves outcomes compared to tamoxifen plus ovarian suppression in premenopausal women with hormone-receptor-positive early breast cancer.
Conducted randomized clinical trials (TEXT, NCT00066703; SOFT, NCT00066690) in premenopausal women with hormone-receptor-positive early breast cancer.
Assigned patients to receive adjuvant exemestane combined with ovarian suppression or tamjuvant tamoxifen combined with ovarian suppression.
Adjuvant exemestane combined with ovarian suppression significantly reduced the risk of breast cancer recurrence compared to tamoxifen plus ovarian suppression.

Cite This Study

Pagani et al. (2014) studied this question.

synapsesocial.com/papers/69d9844d0d540cafc5835fa3 https://doi.org/10.1056/nejmoa1404037

View Full Paper

Ask AI

Bookmark

Implication

Randomized trials demonstrate reduced recurrence with exemestane plus ovarian suppression in premenopausal women, highlighting improved adjuvant endocrine therapy.

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider